HESTERBIO Hester Bios Q3 FY25 results (Oct–Dec 2024) and concall
Hester Biosciences reported a mixed Q3 FY25, with consolidated divisional product sales declining by 6% but 9-month profit growing significantly by 85%. Strong performance in Poultry and Petcare divisions was offset by a 24% decline in Animal Health sales due to external factors and a regulatory ban. International subsidiaries showed improved profitability, with Hester Africa substantially reducing losses, and management anticipates a significant turnaround from this region in the coming quarters.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 74 | 63 |
| EBITDA | 15 | 9 |
| Net profit | 9 | 4 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
